10x Genomics

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
10x Genomics
TickerTXG
CIK #0001770787
CUSIP88025U109
SectorLife Sciences
IndustryLaboratory Analytical Instruments
Phone9254017300
Address6230 Stoneridge Mall Road
Pleasanton, CA 94588
Source [EDGAR]
Market Cap, 13F ($)
1.00.80.60.40.20.02011201320152018
Business

Our mission is to accelerate the mastery of biology to advance human health.

We are a life science technology company building products to interrogate, understand and master biology. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software. Innovations in all of these areas have enabled our rapidly expanding suite of products, which allow our customers to interrogate biological systems at previously inaccessible resolution and scale. Our products have enabled researchers to make fundamental discoveries across multiple areas of biology, including oncology, immunology and neuroscience, and have helped empower the single cell revolution hailed by Science magazine as the 2018 "Breakthrough of the Year" and the technological advancements in single cell multimodal omics hailed by Nature Methods journal as the 2019 "Method of the Year." Our Single Cell ATAC solution was named one of the top 10 life sciences innovations of 2019 by The Scientist magazine. Since launching our first product in mid-2015 through December 31, 2019, we have sold 1,666 instruments to researchers around the world, including 97 of the top 100 global research institutions as ranked by Nature in 2018 based on publications and 19 of the top 20 global biopharmaceutical companies by 2018 revenue. We believe that this represents the very beginning of our penetration into multiple large markets. We expect that 10x will power a "Century of Biology" in which many of humanity's most pressing health challenges will be solved by precision diagnostics, targeted therapies and cures to currently intractable diseases.

The "10x" in our name refers to our focus on opportunities with the greatest potential for exponential advances and impact. We believe that the scientific and medical community currently understands only a tiny fraction of the full complexity of biology. The key to advancing human health lies in accelerating this understanding. The human body consists of over 40 trillion cells, each with a genome of 3 billion DNA base pairs and a unique epigenetic program regulating the transcription of tens of thousands of different RNAs, which are then translated into tens of thousands of different proteins. Progress in the life sciences will require the ability to measure biological systems in a much more comprehensive fashion and to experiment on biological systems at fundamental resolutions and massive scales, which are inaccessible with existing technologies. We believe that our technologies overcome these limitations, unlocking fundamental biological insights essential for advancing human health.

CIK Filing 2011 - 2021
[0001770787] 10-K
[0001770787] 10-Q
[0001770787] 3
[0001770787] 4
[0001770787] 8-K
[0001770787] D
[0001770787] SC 13D
[0001770787] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Paladin Capital Management LLC 10X Genomics Inc [2020-02-18] 23.8
SB Investment Advisers UK Ltd 10X Genomics Inc [2020-02-14] 15.5
Venrock Associates VI LP 10X Genomics Inc [2020-02-14] 34.7
Meritech Capital Partners V LP 10X Genomics Inc [2020-02-14] 12.5
Foresite Capital Fund I LP 10X Genomics Inc [2020-02-14] 25.9
Morgan Stanley 10X Genomics Inc [2020-02-12] 5.1
FMR LLC 10X Genomics Inc [2019-10-10] 0.0
Saxonov Serge 10X Genomics Inc [2019-10-10] 19.9
Hindson Benjamin J 10X Genomics Inc [2019-10-10] 16.9
Form 3/4/5 Filer 2011-2021
Crutchfield Bradford
McAnear Justin J
Hindson Benjamin J
Saxonov Serge
Stuelpnagel John R
Roberts Bryan E
Venrock Associates VI LP
Venrock Partners VI LP
Venrock Partners Management VI LLC
Venrock Management VI LLC
Suliman Shehnaaz
Mammen Mathai
Popovits Kimberly J
Kosaraju Sridhar
Tananbaum James B
Foresite Capital Management II LLC
Foresite Capital Management I LLC
Foresite Capital Fund II LP
Foresite Capital Fund I LP
SB Investment Advisers UK Ltd
Softbank Vision Fund AIV M2 LP
Paladin Holdings III LP
Paladin Homeland Security Corp III Ltd
Steed Michael Robert
Paladin Capital Cyber Group LLC
Paladin Capital Group III LLC
Paladin Capital Management LLC
Paladin Cyber Holdings LP
Paladin Holdings III Cayman Islands LP
Conley Paul A
Foresite Capital Management IV LLC
Foresite Capital Fund IV LP
Shares Owned of 0.0 Total
Firm Period DFND Voting Shares
Morgan Stanley [2020-09-30] DFND 9,113,716.0 9,706,543.0
FMR LLC [2020-09-30] DFND 2,609,314.0 8,586,694.0
Venrock Management VI, LLC [2020-09-30] SOLE 8,185,565.0 8,185,565.0
Vanguard Group Inc [2020-09-30] SOLE 0.0 5,901,412.0
Foresite Capital Management II, LLC [2020-09-30] SOLE 3,503,528.0 3,503,528.0
BlackRock Inc. [2020-09-30] SOLE 3,108,174.0 3,288,510.0
Foresite Capital Management I, LLC [2020-09-30] SOLE 2,750,000.0 2,750,000.0
FIL Ltd [2020-09-30] DFND 2,471,355.0 2,479,455.0
12 West Capital Management LP [2020-09-30] SOLE 1,922,000.0 1,922,000.0
Invesco Ltd. [2020-09-30] DFND 0.0 1,792,833.0
Capital World Investors [2020-09-30] DFND 1,276,870.0 1,276,870.0
AllianceBernstein LP [2020-09-30] DFND 1,112,994.0 1,230,456.0
Nuveen Asset Management LLC [2020-09-30] DFND 1,001,406.0 1,001,406.0
Franklin Resources Inc [2020-09-30] DFND 801,087.0 801,087.0
Ameriprise Financial Inc [2020-09-30] DFND 0.0 765,096.0
Gilder Gagnon Howe & Co LLC [2020-09-30] DFND 0.0 688,611.0
Geode Capital Management LLC [2020-09-30] DFND 685,682.0 685,749.0
Price T Rowe Associates Inc /MD/ [2020-09-30] SOLE 146,918.0 679,114.0
RTW Investments LP [2020-09-30] SOLE 660,933.0 660,933.0
Credit Suisse AG [2020-09-30] DFND 659,600.0 659,600.0
Bank of New York Mellon Corp [2020-09-30] DFND 589,676.0 646,963.0
JS Capital Management LLC [2020-09-30] SOLE 606,400.0 606,400.0
State Street Corp [2020-09-30] DFND 480,217.0 563,394.0
Baillie Gifford & Co [2020-09-30] DFND 428,950.0 511,447.0
CaaS Capital Management LP [2020-09-30] SOLE 499,456.0 499,456.0
Lord Abbett & Co LLC [2020-09-30] SOLE 496,562.0 496,562.0
BAMCO Inc /NY/ [2020-09-30] DFND 0.0 487,037.0
Schwab Charles Investment Management Inc [2020-09-30] SOLE 428,763.0 428,763.0
Goldman Sachs Group Inc [2020-09-30] DFND 351,142.0 402,034.0
Waddell & Reed Financial Inc [2020-09-30] DFND 365,421.0 365,421.0
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com